The higher expression of PD-L1, CD8A, GZMA, and PRF1 in type I and II ovarian cancer indicated that these patients would tend to gain more benefit from anti-PD-1/PD-L1 therapy. This evidence concerns the gene CD274 and ovarian carcinoma.